Physician profile
Anne Griffin
NPI 1699974741
$7,088.61
in general payments reported to CMS, 2019-2025
19 companies · $3,022 in 2025
The $3,022 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $151 · 2021: $441 · 2022: $1,192 · 2023: $730 · 2024: $1,004 · 2025: $3,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063 · Consulting Fee: $1,688 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.43 |
| Consulting Fee | $1,687.69 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,510.35 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $952.60 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $886.66 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Alcon Vision LLC | $623.84 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Abbvie INC. | $543.08 | 2022-2025 | |
| Coopervision INC. | $399.64 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $365.61 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $157.31 | 2019-2025 | |
| Oyster Point Pharma, INC. | $145.44 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $125.68 | 2019-2022 | |
| Allergan, INC. | $95.34 | 2021-2022 | |
| Glaukos Corporation | $76.17 | 2021 | |
| Kala Pharmaceuticals, INC. | $53.84 | 2021 | |
| Dompe US, INC. | $37.03 | 2023-2024 | Oxervate |
| Biotissue Holdings INC. | $30.75 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.10 | 2019 | |
| Spark Therapeutics, INC. | $23.60 | 2022 | |
| Topcon Healthcare, INC. | $22.83 | 2022 | |
| Aerie Pharmaceuticals, INC. | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.